Background pattern of a brain with neural connections
Fabio Blandini

Fabio Blandini

Co-PI (Core Leadership)

IRCCS Ca' Granda Ospedale Maggiore Policlinico

Fabio Blandini is currently Scientific Director of the Mondino National Institute of Neurology – a research hospital funded by the Italian Ministry of Health – and full professor of neuropharmacology at the Dept. of Brain and Behavioral Sciences of the University of Pavia. He is also chair of the Pan-European Committee of IBRO (https://ibro.org/pan-europe-committee/) and member of the European Brain Council (https://www.braincouncil.eu/about-us/full-members/). He obtained his MD degree in 1986, then specialized in neurology in 1990 and biochemistry in 2001. His research interests are focused on the investigation of the pathogenesis and the search for innovative therapeutics of Parkinson’s disease through pre-clinical models and clinical studies in patients.

Teams

Schapira

Themes

Circuitry and Brain-Body Interactions

Tags

Central Nervous System (CNS) Mouse Mass Spectrometry Proteomics Laser capture microdissection (LCM) PNS (Peripheral Nervous System) Single-cell analysis

Recent ASAP Preprints & Published Papers

Severe GBA1 variants drive the GBA-PD clinical phenotype: implications for counselling and clinical trials

**Background** Variants in the *GBA1* gene are the commonest genetic risk factor for Parkinson disease (PD). Genotype-phenotype correlations exist but with conflicting data, particularly in the cognitive domain. **Objectives** Comparing clinical phenotypes in a multicentre, international cohort incorporating GBA-PD and idiopathic PD (iPD) patients. **Methods** Patients underwent a comprehensive assessment of motor and non-motor functions.…

Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach

Purpose of Review Genetic variants in GBA1 and LRRK2 genes are the commonest genetic risk factor for Parkinson disease (PD); however, the preclinical profile of GBA1 and LRRK2 variant carriers who will develop PD is unclear. This review aims to highlight the more sensitive markers that can stratify PD risk…

Team Schapira

Anthony Schapira

Anthony Schapira

Lead PI (Core Leadership)
Mathieu Almeida

Mathieu Almeida

Co-PI (Core Leadership)
Fabio Blandini

Fabio Blandini

Co-PI (Core Leadership)
Michela Deleidi

Michela Deleidi

Co-PI (Core Leadership)
Donato Di Monte

Donato Di Monte

Co-PI (Core Leadership)
Sofia Koletsi

Sofia Koletsi

Project Manager

Our Research Teams

Members of the CRN work diligently to advance our understanding of Parkinson’s disease. Learn more about recent CRN discoveries and achievements.

Explore the Research Community